Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot, Randomized, Open-Label Trial of the Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV

NCT07871552 is registered in ClinicalTrials.gov with The University of Texas Health Science Center, Houston as lead sponsor.

NCT NCT07871552
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07871552 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot, Randomized, Open-Label Trial of the Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV
Lead sponsor
The University of Texas Health Science Center, Houston
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 30, 2026
Completion date
October 15, 2028
Enrollment
60 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

epigenetic aging